These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
74 related articles for article (PubMed ID: 27127153)
1. Ifosfamide and Etoposide Chemotherapy in the Treatment of Recurrent/Refractory Rhabdomyosarcoma in Adults. Sasada S; Kodaira M; Shimoi T; Shimomura A; Yunokawa M; Yonemori K; Shimizu C; Fujiwara Y; Tamura K Anticancer Res; 2016 May; 36(5):2429-32. PubMed ID: 27127153 [TBL] [Abstract][Full Text] [Related]
2. Treatment of intermediate risk rhabdomyosarcoma and undifferentiated sarcoma with alternating cycles of vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide. Arndt CA; Nascimento AG; Schroeder G; Schomberg PJ; Neglia JP; Sencer SF; Silberman TL; Moertel CL; Tillisch JK; Miser JS Eur J Cancer; 1998 Jul; 34(8):1224-9. PubMed ID: 9849484 [TBL] [Abstract][Full Text] [Related]
3. Experience with ifosfamide and etoposide combination chemotherapy in extensive-disease small-cell lung cancer. Wu MF; Perng RP; Chen YM; Liu JM; Yang SL; Whang-Peng J Zhonghua Yi Xue Za Zhi (Taipei); 1997 Aug; 60(2):67-73. PubMed ID: 9360330 [TBL] [Abstract][Full Text] [Related]
4. Ifosfamide, carboplatin, and etoposide (ICE) reinduction chemotherapy in a large cohort of children and adolescents with recurrent/refractory sarcoma: the Children's Cancer Group (CCG) experience. Van Winkle P; Angiolillo A; Krailo M; Cheung YK; Anderson B; Davenport V; Reaman G; Cairo MS Pediatr Blood Cancer; 2005 Apr; 44(4):338-47. PubMed ID: 15503297 [TBL] [Abstract][Full Text] [Related]
5. A feasibility, toxicity, and early response study of etoposide, ifosfamide, and vincristine for the treatment of children with rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study (IRS) IV pilot study. Arndt C; Tefft M; Gehan E; Anderson J; Jenson M; Link M; Donaldson S; Breneman J; Wiener E; Webber B; Maurer H J Pediatr Hematol Oncol; 1997; 19(2):124-9. PubMed ID: 9149741 [TBL] [Abstract][Full Text] [Related]
6. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy. Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ifosfamide in combination with carboplatin and etoposide in small cell lung cancer. Lee HS; Lee YG; Koo DH; Oh S; Nam H; Song JU; Lim SY; Lim SY; Lee SS Cancer Chemother Pharmacol; 2015 Nov; 76(5):933-7. PubMed ID: 26374553 [TBL] [Abstract][Full Text] [Related]
8. Comparison of results of a pilot study of alternating vincristine/doxorubicin/cyclophosphamide and etoposide/ifosfamide with IRS-IV in intermediate risk rhabdomyosarcoma: a report from the Children's Oncology Group. Arndt CA; Hawkins DS; Meyer WH; Sencer SF; Neglia JP; Anderson JR Pediatr Blood Cancer; 2008 Jan; 50(1):33-6. PubMed ID: 17091486 [TBL] [Abstract][Full Text] [Related]
9. Randomized comparison of intensified six-drug versus standard three-drug chemotherapy for high-risk nonmetastatic rhabdomyosarcoma and other chemotherapy-sensitive childhood soft tissue sarcomas: long-term results from the International Society of Pediatric Oncology MMT95 study. Oberlin O; Rey A; Sanchez de Toledo J; Martelli H; Jenney ME; Scopinaro M; Bergeron C; Merks JH; Bouvet N; Ellershaw C; Kelsey A; Spooner D; Stevens MC J Clin Oncol; 2012 Jul; 30(20):2457-65. PubMed ID: 22665534 [TBL] [Abstract][Full Text] [Related]
11. Ifosfamide- and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma. Mayer J; Vásová I; Korístek Z; Navrátil M; Klabusay M; Doubek M; Vorlícek J; Cernilová I; Vodvárka P; Petráková K Eur J Haematol Suppl; 2001 Jul; 64():21-7. PubMed ID: 11486396 [TBL] [Abstract][Full Text] [Related]
12. Epirubicin and ifosfamide in relapsed or refractory small cell lung cancer patients. Jacot W; Pujol JL; Chakra M; Molinier O; Bozonnat MC; Gervais R; Quantin X Lung Cancer; 2012 Feb; 75(2):213-6. PubMed ID: 21831476 [TBL] [Abstract][Full Text] [Related]
14. Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide/carboplatin/etoposide (ICE): A phase II study in a pediatric oncology centre in Brazil. Loss JF; Santos PP; Leone LD; Brunetto AL Pediatr Blood Cancer; 2004 Feb; 42(2):139-44. PubMed ID: 14752877 [TBL] [Abstract][Full Text] [Related]
15. Regional deep hyperthermia for salvage treatment of children and adolescents with refractory or recurrent non-testicular malignant germ-cell tumours: an open-label, non-randomised, single-institution, phase 2 study. Wessalowski R; Schneider DT; Mils O; Friemann V; Kyrillopoulou O; Schaper J; Matuschek C; Rothe K; Leuschner I; Willers R; Schönberger S; Göbel U; Calaminus G; Lancet Oncol; 2013 Aug; 14(9):843-52. PubMed ID: 23823158 [TBL] [Abstract][Full Text] [Related]
16. Peripheral blood stem cell support reduces the toxicity of intensive chemotherapy for children and adolescents with metastatic sarcomas. Hawkins DS; Felgenhauer J; Park J; Kreissman S; Thomson B; Douglas J; Rowley SD; Gooley T; Sanders JE; Pendergrass TW Cancer; 2002 Sep; 95(6):1354-65. PubMed ID: 12216105 [TBL] [Abstract][Full Text] [Related]
18. Phase II study of combination chemotherapy with etoposide and ifosfamide in patients with heavily pretreated recurrent or persistent epithelial ovarian cancer. Kang H; Kim TJ; Choi CH; Lee JW; Lee JH; Bae DS; Kim BG J Korean Med Sci; 2009 Oct; 24(5):945-50. PubMed ID: 19794997 [TBL] [Abstract][Full Text] [Related]